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S290 Poster Session Irelapse. Five pts have died (median 9 months), 2 from graft-versus-
host disease (GVHD), 2 infections, and 1 elected Hospice care after
experiencing renal failure. Last disease responses were complete re-
mission (n5 8), partial remission (n5 6), stable disease (n5 5), not-
evaluated (n 5 1). The incidences of grades II and III-IV acute
GVHD were 60% and 15% respectively, and chronic GVHD was
46% at 1-year. Estimated 1-year rate of non-relapse mortality
(NRM), relapse, progression-free (PFS), and overall survivals (OS)
were 33%, 0%, 67%, and 67% respectively. Patients receiving
peri-HCT rituximab had lower HR for relapse (HR:0, p 5 0.001),
comparable HR for NRM (HR:1, p 5 0.9) and OS (HR:0.7, p 5
0.45), and a trend for lower HR for PFS (HR:0.5, p 5 0.07)
compared to the historical control group. At day 84, median CD3
chimerisms were 99% vs 95% (p 5 0.08), respectively.
After adjusting for the previous 4 significant covariates, PFS was
better (HR:0.4, p 5 0.04) among the rituximab group. Peri-
transplant rituximab is a promising addition to nonmyeloablative
HCT and may decrease early disease progression by allowing the
generation of potent GVL effects.231
LEUKEMIC TRANSFORMATION OF PHILADELPHIA-NEGATIVE MYELO-
PROLIFERATIVE NEOPLASMS: RESULTS OF A TREATMENT ALGORITHM
EMPLOYING ALLOGENEIC TRANSPLANTATION USING RELATED AND
UNRELATED DONORS
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Leukemic transformation (LT) is a rare but fatal complication of
Philadelphia-negative myeloproliferative neoplasms (MPNs) for
which optimal treatment strategies are not known. LT is generally
considered incurable with induction chemotherapy alone.
At our centre, we have adopted a treatment strategy for LT
where patients within the transplant age group who have a reason-
able fitness level are offered induction therapy. Subsequently, those
who achieve complete remission (CR/CRi) or revert back to
a chronic MPN (cMPN) state are considered eligible for allogeneic
transplantation (allo-SCT) if a suitable related or unrelated donor
is available. Alternatively, those who are not candidates for the
aforementioned strategy are offered supportive therapy including
clinical trials.
We evaluated clinical outcomes of this treatment approach in 75
patients with LT diagnosed between 1998 and 2011. Prior to LT,
MPN diagnoses were: PV, 16%; ET, 16%; primary MF, 28%;
post-PV/ET MF, 25%; and MPN-U, 15%. 39 (52%) patients
were treated with curative intent (induction chemotherapy +/-
allo-SCT) while the remainder were treated with non-curative in-
tent. At the time of LT, the curative intent cohort differed from
the non-curative group in terms of median age (57 vs. 72 yrs,
P\0.0001), performance status (ECOG#1 in 92% vs. 58%, p 5
0.001), serum albumin (38 vs. 35 g/L, p 5 0.008) and the frequency
of normal cytogenetics (47% vs. 20%, p 5 0.03) respectively.
Among all patients, the 2-year overall survival (OS) from the time
of LT was 15%. Outcomes were significantly improved in individ-
uals treated with curative vs. non-curative intent (2-year OS, 25%
vs. 4%, P\ 0.0001). Among the curative group, 30/39 achieved ei-
ther CR (n 5 19) or reversion to cMPN (n 5 11). Suitable donors
were identified for 24 (80%) of these responders and 17 (57%) un-
derwent allo-SCT.Median time to transplant was 177 days. Survival
of patients undergoing allo-SCT was significantly better compared
to those who achievedCR/cMPNpost-induction but were not trans-
planted (2-year OS, 46% (n5 17) vs. 15% (n5 13), P5 0.035). To
avoid a time to transplant bias, a landmark analysis was done compar-
ing survival between the transplant cohort and non-transplanted pa-
tients who survived at least 177 days (n5 13), and similar results were
observed (2-year OS 46% vs. 15%, p 5 0.035).
Our results demonstrate the curative potential of intensive induc-
tion therapy followed by allo-SCT in select patients with LT pre-
ceded by MPN.232
LOW DAY 100 TRANSPLANT-RELATED MORTALITY (TRM) FOLLOWING
CLOFARABINE (CLO) IN COMBINATION WITH CYTARABINE AND TOTAL
BODY IRRADIATION (TBI), MYELOABLATIVE CONDITIONING (MAC)
AND ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT) IN CHIL-
DREN, ADOLESCENTS AND YOUNG ADULTS (CAYA) WITH POOR-RISK
ACUTE LEUKEMIA
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Background:CAYA with ALL or AML in third complete remission
(CR3), refractory relapse (RR) or induction failure (IF) have an ex-
tremely poor prognosis,\20% EFS (Gaynon, BJH, 2005, Wells et
al, JCO, 2003). MAC prior to AlloSCT is associated with high
TRM and is donor dependent: 5-20% for matched sibling, 10-
40% for matched unrelated, and 20-52% for cord blood transplants.
CLO, an inhibitor of DNA polymerase and ribonucleotide reduc-
tase, has been shown to be safe and induce durable remissions,
both in conjunction with busulfan in poor-risk AML (Magenau et
al., Blood, 2011) and with Melphalan in poor-risk hematologic ma-
lignancies in adults (van Besien et al, ASH,2009). CLO has signifi-
cant activity in CAYA with relapsed ALL/AML (Jeha et al., JCO
2006,2009) and synergy with cytarabine (Faderl et al, Blood,
2005). We sought to determine safety, day-100 TRM, and overall
survival (OS) of CLO, cytarabine and TBI followed by AlloSCT in
CAYA with poor-risk ALL/AML.
Methods: This is an ongoing multi-center phase I/II trial of a novel
conditioning regimen of CLO (dose escalation: 40mg/m2 [n5 3], 46
mg/m2 [n 5 3], 52 mg/m2 [n 5 17]) x5d, sequential (4 hrs later) cy-
tarabine 1000 mg/m2 x6d and TBI (1200cGy) followed by AlloSCT
frommatched related or unrelated donors in CAYA with ALL/AML
in CR3, RR or IF. Pts with unrelated grafts received R-ATG.
GVHDprophylaxis consisted of tacrolimus andMMF (Bhatia/Cairo
et al., BBMT, 2009). Kaplan-Meier method was used to determine
the probabilities of engraftment, GVHD, TRM and OS.
Results: 23 pts, median age: 10.8 yrs (1.5-20.7); M:F: 17:6, ALL/
AML: 20:3 (9 CR3, 3 RR, 11 IF), 9 related donors, 14 unrelated do-
nors (8 BM/PBSCs, 6 UCB). Median TNC and CD34 dose was
4.76x108/kg and 4.84x106/kg for BM/PBSCs and 4.0x107/kg and
2.8x105/kg for UCB, respectively. Probabilities of neutrophil and
platelet engraftment and grade II-IV aGVHD were 100%, 92.8%
and 50.8%, respectively. All except one achieved 100% whole blood
donor chimerism by day 30. CLO dose was tolerable at 52mg/m2/
d x5d without dose limiting toxicity. Probability of Day 100 TRM
was only 5%. Probability of 1-yr PFS and OS were 45% (CI95: 24-
83%), and 44.6% (CI95: 24-68%) respectively.
Conclusions: Preliminary results suggest this novel MAC regimen
followed by AlloSCT is safe and well tolerated in CAYA with
poor-risk ALL/ AML with CLO dose of 52 mg/m2. Early results
are encouraging with respect to low risk of day 100 TRM with this
conditioning regimen in this poor-risk population.233
OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
(HCT) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): IMPACT OF MYE-
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There has been a marked change in transplant approaches of the
CLL patient. MA conditioning has been shown to provide high
Poster Session I S291complete remission (CR) rates and long-term survival, however, it
remains associated with significant treatment related mortality
(TRM) and it remains unclear whether aCT - orTBI-basedMA reg-
imen is most efficacious. RIC has also been shown to achieve durable
long-term survival with a lower TRM (15-25%) and has been gener-
ally used for older patients. To attempt to compare these procedures
an analysis of CLL patients undergoing first Human Leukocyte An-
tigen (HLA)-matched sibling donor (MRD)HCTbetween 1995 and
2007was performed, focusing on differences between: 1)MA vs. RIC
transplants; and 2) CT- vs. TBI-based MA conditioning.
Among 297 patients, 163 MA vs. 134 RIC, significant differences
in baseline characteristics included:Median age; source of stem cells;
median donor age; use of antithymocyte globulin (ATG); graft ver-
sus host disease (GVHD) prophylaxis; and the year of transplanta-
tion. Multivariate analysis demonstrated that MA conditioning was
associated with a higher incidence of acute GVHD (p 5 0.002)
and a higher TRM (p 5 0.003), but a lower relapse rate (p 5
0.005). Although there was no difference in survival before year
2000, after year 2000, MA conditioning was associated with reduced
survival by almost 2-fold (p 5 0.019).
Among 163 patients who had MA conditioning, 110 were TBI-
based and 53 were CT-based. Significant differences in baseline
characteristics were: Rai stage at diagnosis, stem cells source, and
the use of ATG (0 vs. 11%, p\0.001). As compared to the CT-based
transplants those with TBI tended to be performed earlier with the
majority being before year 2000 (p 5 0.052). Although there were
no significant differences between the groups regarding GVHD,
neutrophil engraftment, relapse or survival, the CT-based condi-
tioning group had higher TRM (p 5 0.006) and treatment failure
risk.
We conclude from this large retrospective comparison that RIC
HCT from a MRD is effective in an older CLL population with su-
perior survival and less TRM than that observed withMA condition-
ing. However, due to the higher relapse rate in the RIC group, future
strategies to enhance the anti-leukemic effect are warranted. In the
MA setting, TBI-based conditioning may be superior to a CT-based
approach; however, recognizing the emerging efficacy of RICHCT,
a prospective comparison is unlikely to be performed.234
PRECLINICAL MODEL TO PREDICT ANTI-LEUKEMIC ACTIVITY OF
BUSULFAN AND IRRADIATION
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We tested the in vitro effect of physiologic doses of busulfan (Bu)
and ionizing radiation (IR) to address whether additive antileukemic
activity can be demonstrated in two leukemic cell lines, one sensitive
(HL60) and one resistant (K562) to radiation. Cells were treated for
24 hours with Bu doses ranging from at 0 to 200 mg/ml, or IR at 1.5, 3
or 6 Gy, or with BU at 12.5 or 25 mg/ml for 24 hours, followed by IR
at 1.5 or 3Gy. Cells were then tested for proliferation, expression of
annexin-V and caspase-3, and colony formation. Exposure to Bu or
IR induced a variable but dose dependent inhibition of proliferation
and colony formation in HLA-60 cells. On the contrary, we could
observe a significant cytotoxic effect in K562 cells by using IR at 6,
but not 1.5 or 3.0 Gy (p5 0.008). In addition, treatment with either
Bu or IR caused apoptosis with increased caspase-3 expression in
HL60 cells, but not in K562 cells. To test a possible synergistic effect
of the combination of Bu and IR, we treated the cells with Bu for 24
hours followed by radiation. HL60 cells were strongly inhibited by
both agents when separate or combined. In contrast, treatment of
K562 cells with low dose IR (3Gy) alone inhibited colony formation
by 28% and with low dose Bu by 77%. The inhibitory effect of low
dose Bu + IR 3Gy increased up to 86%, suggesting that Bu could in-
duce radio-resistant leukemic cells to become more radio-sensitive.
In order to identify genes associated with a response to Bu, we
formed a linear regression model controlled for cancer type using
GI50 and Stanford cDNA array data from the NCI-60. 7 genes
were identified that strongly correlated with response (p\0.001
and FDR 50%). The most significant genes were then tested in
the Affymetric U133 plus 2.0 platform. Our analysis identified sixgenes (ERC2, HCLS1, CD74, KCNH2, HLADQB2, CD53) which
are significantly associated with response to Bu (p\0.05). Our in-
vitro study demonstrated an additive effect of Bu and low dose IR
even on radioresistant leukemic cells. The identification of a genomic
signature for response to Bu validated by in vitro functional assays
represents a novel approach for a personalized chemo-radiotherapy
in patients with AML undergoing an allogeneic stem cell transplant.235
TARGETING LEUKEMIA BY CD123 SPECIFIC CHIMERIC ANTIGEN
RECEPTOR
Thokala, R., Olivares, S., Singh, H., Champlin, R.E., Cooper, L.J.N.MD
Anderson Cancer Center, Houston, TX
Chimeric antigen receptors (CARs) are employed to genetically
modify T cells to redirect their specificity to target antigens on tu-
mor cells. Typically a second generation CAR is derived by fusing
an extracellular domain derived from the scFv of monoclonal anti-
body (CAR) specific to targeted antigen with CD3z, and CD28 en-
dodomains. CD123 (IL3RA) is expressed on 45% to 95% of acute
myelogenous leukemia (AML) and B-cell lineage acute lymphoblas-
tic leukemia (B-ALL). Expression of CD123 is high in the leukemic
stem cell (LSC) population, but not in normal hematopoietic stem
cells. Thus, CD123 appears to be potential target for immunother-
apy in leukemias through chimeric antigen receptor (CAR). We hy-
pothesized that the generation of CD123 specific CAR can redirect
the specificity of T cells to CD123 and this was tested by cloning the
scFv of CD123mAb in our CAR construct. The sleeping beauty sys-
tem was used to express the CAR and DNA plasmids were electro-
porated into peripheral blood mononuclear cells and cells were
numerically expanded on artificial antigen presenting cells geneti-
cally modified to express co stimulatory molecules CD86, 4-1BBL,
membrane-bound IL-15, and CD123 antigen in presence of IL-21
and 1L-2. CAR+T numerically expanded to clinically relevant num-
bers and showed antigen specific cytotoxicity in leukemic celllines.
CAR+ T cells expressed both effector and memory markers showing
the potential for in vivo persistence after T cell infusion. The bone-
marrow homing receptor CXCR4 was expressed by CAR T cells
shows the potential to target LSC that reside in BM niches. The pre-
liminary data suggests that mirroring an approach we are using to
manufacture clinical grade CD19 specific CAR+ T cells.236
INCREASED ABILITY TO TRANSPLANT AND IMPROVED SURVIVAL IN
PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKEMIA (AML) AFTER
INDUCTION WITH HIGH DOSE CYTARABINE AND MITOXANTRONE
(HIDAC/MITO)
Ramanathan,M., Cerny, J., Raffel, G., Petrillo-Deluca, L., Tarrasky, N.,
Nath, R. UMass Memorial Medical Center, Worcester, MA
Background: Patients with high risk AML have a poor prognosis
and inferior outcomes after 7+3 induction. Complete remission
(CR) rates range from 6-51% and induction death rates between
9-48%. We present a single institution experience in high risk
AML patients treated with HIDAC/MITO induction regimen
(Blood 2010; 116: 3290).
Methods: We have retrospectively analyzed the outcome of 43 pa-
tients with AML who received HiDAC/MITO induction at our in-
stitution from January 2009- September 2011. High risk features
included at least one of the following such as age.60, high risk cy-
togenetics, high age adjusted Charlson comorbidity index (CCI)
and non denovo AML (therapy related, antecedent hematological
disorder or relapsed AML). The endpoints analysed were CR (mar-
row blasts\5%) at day 30, induction mortality within 30 days of in-
duction, ability to proceed to transplant, number of days to
transplant, overall survival (OS) and progression free survival
(PFS) of transplanted vs non transplanted patients, calculated from
day 1 of induction.
Patient characteristics:Themedian age was 67 years (47 - 83), me-
dian age adjusted CCI was 6 (4 -12), 26 (60%) were males and 17
